Cancer Patients' egg freezing: which trigger works best?

NCT ID NCT07546136

Recruiting now Disease control Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at two ways to trigger ovulation in women with cancer who are freezing their eggs before chemotherapy. One method uses a GnRH agonist alone, the other combines it with hCG (dual trigger). The goal is to see which approach retrieves more eggs while reducing the risk of a complication called ovarian hyperstimulation syndrome (OHSS). About 200 patients will be enrolled and assigned to one of the two groups based on their clinical needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: triptorelin (GnRH agonist) with or without urinary hCG
What this could lead to: If successful, this could identify the best way to trigger ovulation in cancer patients, helping them retrieve more eggs for fertility preservation before chemotherapy.
What could go wrong: This is a small, early-stage study (200 patients) comparing two standard approaches, so it may not show a clear winner. The dual trigger may increase the risk of ovarian hyperstimulation syndrome (OHSS).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FERTILITY PRESERVATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FERTILITY PRESERVATION ONCOLOGICAL DISEASE

Contacts and locations

Locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITING

Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.